11 recruiting, 8 active not recruiting, 3 not yet recruiting, 3 unknown. 18 Phase 2, 16 Phase 1, 3 Phase 3, 1 Not applicable.
Follow Advanced Urothelial Carcinoma: new trials by email Literature Review of Advanced Urothelial Carcinoma trials Research Report on Advanced Urothelial Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immunotherapy Plus Capivasertib for Metastatic Bladder Cancer capivasertib - Advanced Urothelial Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | VA Office of Research and Development | 32 | 2027-01-01 | 2026-10-05 |
| Zanzalintinib for Advanced Urothelial Carcinoma Progressing After Prior Therapy Zanzalintinib - Advanced Urothelial Carcinoma | Phase 2 | Not yet recruiting | Guru Sonpavde | 44 | 2026-10-01 | 2026-09-02 |
| Rimegepant Plus Toripalimab in Advanced Urothelial Carcinoma After Failure of Standard Therapy Rimegepant, Toripalimab - Advanced Urothelial Carcinoma | Phase 1 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 12 | 2026-07-06 | 2026-09-22 |
| SYS6002 vs PADCEV in Patients With Advanced Urothelial Carcinoma SYS6002, enfortumab vedotin - Advanced Urothelial Carcinoma | Phase 2 | Not yet recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 100 | 2026-06-20 | 2026-01-29 |
| Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma Enfortumab vedotin, Pembrolizumab - Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma | Phase 2 | Recruiting | Fox Chase Cancer Center | 97 | 2026-01-23 | 2026-02-19 |
| Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) Adebrelimab, Trastuzumab Rezetecan - Urothelial Carcinoma, Advanced Urothelial Carcinoma | Phase 2 | Recruiting | Sun Yat-sen University | 96 | 2025-11-20 | 2026-04-30 |
| Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer copanlisib, Avelumab - Advanced Urothelial Carcinoma | Phase 1 / Phase 2 | Withdrawn | VA Office of Research and Development | 2025-06-02 | 2025-06-15 | |
| A Biomarker Study to Predict Treatment Outcomes of Enfortumab Vedotin in Advanced Urothelial Carcinoma Biomarker Analysis - Advanced Urothelial Carcinoma | Active not recruiting | National Taiwan University Clinical Trial Center | 200 | 2025-04-01 | 2025-07-16 | |
| A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma SHR-A2102 for Injection, Docetaxel Injection, Paclitaxel Injection - Advanced Urothelial Carcinoma | Phase 3 | Recruiting | Shanghai Hengrui Pharmaceutical Co., Ltd. | 402 | 2025-02-12 | 2025-07-17 |
| Probiotics in Advanced Urothelial Carcinoma Probiotics Compound (Biolosion), Nab-paclitaxel, Cisplatin - Advanced Urothelial Carcinoma, Probiotics | Phase 2 | Recruiting | Sun Yat-sen University | 222 | 2025-01-01 | 2025-04-01 |
| A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma SHR-A2102, Adebrelimab injection, SHR-8068 injection - Advanced Urothelial Carcinoma | Phase 1 / Phase 2 | Recruiting | Shanghai Hengrui Pharmaceutical Co., Ltd. | 90 | 2024-11-04 | 2024-11-18 |
| A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer 9MW2821, Chemotherapy - Advanced Urothelial Carcinoma | Phase 3 | Recruiting | Mabwell (Shanghai) Bioscience Co., Ltd. | 432 | 2023-12-29 | 2025-04-13 |
| Clofarabine Therapy in Locally Advanced or Metastatic Urothelial Carcinoma Clofarabine - Advanced Urothelial Carcinoma, Metastatic Urothelial Cancer | Phase 1 / Phase 2 | Recruiting | Ekaterina Laukhtina | 50 | 2023-10-24 | 2025-06-26 |
| 9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer 9MW2821, Toripalimab - Advanced Urothelial Carcinoma | Phase 1 / Phase 2 | Recruiting | Mabwell (Shanghai) Bioscience Co., Ltd. | 100 | 2023-09-27 | 2024-09-19 |
| A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma FX-909, Pembrolizumab (KEYTRUDA ®), KEYTRUDA ®( Pembrolizumab) - Advanced Urothelial Carcinoma, Oral Drug Administration | Phase 1 | Active not recruiting | Flare Therapeutics Inc. | 120 | 2023-08-24 | 2026-08-12 |
| Magrolimab in Combination With Cytotoxic Chemotherapy in Advanced Urothelial Carcinoma Magrolimab, Cisplatin, Gemcitabine - Advanced Urothelial Carcinoma | Phase 1 | Withdrawn | Insel Gruppe AG, University Hospital Bern | 2023-06-21 | 2024-07-05 | |
| CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors Biospecimen Collection, Computed Tomography, Devimistat - Advanced Biliary Tract Carcinoma, Advanced Colorectal Carcinoma | Phase 2 | Recruiting | Northwestern University | 94 | 2023-03-08 | 2023-03-10 |
| Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations TYRA-300 - Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma | Phase 1 / Phase 2 | Active not recruiting | Tyra Biosciences, Inc | 310 | 2022-11-22 | 2026-01-12 |
| A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer Pembrolizumab, FF-10832 - Advanced Urothelial Carcinoma, Advanced Non Small Cell Lung Cancer | Phase 2 | Active not recruiting | Fujifilm Pharmaceuticals U.S.A., Inc. | 120 | 2022-06-01 | 2025-09-04 |
| Postoperative Adjuvant Immunotherapy Combined with Radiotherapy Versus Surgery Alone in Locally Advanced UTUC Immunotherapy+radiotherapy, surveillance alone - Ureter Cancer, Renal Pelvic Carcinoma | Recruiting | Peking University First Hospital | 60 | 2022-01-01 | 2024-11-05 |
Showing 20 of 31. Sign in to see all of them.
Carcinoma, Transitional Cell (8) · Lung Neoplasms (3) · Neoplasm Metastasis (3) · Ovarian Neoplasms (3) · Prostatic Neoplasms (3) · Ureteral Neoplasms (3) · Carcinoma, Renal Cell (2) · Triple Negative Breast Neoplasms (2) · Urinary Bladder Neoplasms (2) · Adenocarcinoma of Lung (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Medullary (1) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · HIV Infections (1)
Neoplasms (13) · Neoplasms by Histologic Type (10) · Neoplasms, Glandular and Epithelial (10) · Carcinoma (9) · Female Urogenital Diseases (9) · Female Urogenital Diseases and Pregnancy Complications (9) · Neoplasms by Site (9) · Urogenital Diseases (9) · Male Urogenital Diseases (8) · Urogenital Neoplasms (8) · Urologic Diseases (6) · Genital Diseases (5) · Urologic Neoplasms (5) · Genital Diseases, Male (4) · Genital Neoplasms, Male (4)
Gemcitabine (6) · pembrolizumab (6) · Cisplatin (4) · enfortumab vedotin (3) · toripalimab (3) · 1,2-diaminocyclohexaneplatinum II citrate (2) · Docetaxel (2) · Magnetic Resonance Spectroscopy (2) · Paclitaxel (2) · Platinum (2) · Specimen Handling (2) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · BAY 1895344 (1) · Bevacizumab (1)
National Cancer Institute (NCI) (4) · Mabwell (Shanghai) Bioscience Co., Ltd. (2) · Shanghai Hengrui Pharmaceutical Co., Ltd. (2) · Sun Yat-sen University (2) · VA Office of Research and Development (2) · Asan Medical Center (1) · CSPC Megalith Biopharmaceutical Co.,Ltd. (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Ekaterina Laukhtina (1) · Flare Therapeutics Inc. (1) · Fox Chase Cancer Center (1) · Fujifilm Pharmaceuticals U.S.A., Inc. (1) · Guru Sonpavde (1) · Insel Gruppe AG, University Hospital Bern (1) · Lee's Pharmaceutical Limited (1)
United States (15) · China (10) · South Korea (2) · Spain (2) · Australia (1) · Austria (1) · Canada (1) · France (1) · Puerto Rico (1) · Taiwan (1) · United Kingdom (1)
Chong-Xian Pan, MD PhD (2) · Mamta Parikh (2) · Yanxia Shi, Doctor (2) · Bernhard Kiss, Professor (1) · David I Quinn (1) · Devalingam Mahalingam (1) · Doug Warner (1) · Fu-Jen Hsueh, M.D. (1) · Gopa Iyer, MD (1) · Guru Sonpavde, MD (1) · Haiying Cheng (1) · Jonathan E Rosenberg (1) · Lawrence Fong, MD (1) · Pooja Ghatalia, MD (1)
PMID 31668839, PMID 33989025, PMID 37919668, PMID 38573872, PMID 39418340, PMID 40256659, PMID 40288679, PMID 40591902, PMID 41760953, PMID 42847673
UM1CA186717 (2), 2015 (1), 2023 (1), N01CM00038 (1), N01CM00071 (1), N01CM62201 (1), N01CM62209 (1), P30CA033572 (1), P30CA060553 (1), P30CA093373 (1), U01CA062505 (1), U10CA031946 (1), U10CA180821 (1), UM1CA186705 (1)